|
AU5438299A
(en)
*
|
1998-08-29 |
2000-03-21 |
Astrazeneca Ab |
Pyrimidine compounds
|
|
US20040226056A1
(en)
*
|
1998-12-22 |
2004-11-11 |
Myriad Genetics, Incorporated |
Compositions and methods for treating neurological disorders and diseases
|
|
EP2298311B1
(de)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
CA2366932C
(en)
|
1999-04-15 |
2009-08-25 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
|
MXPA02003436A
(es)
|
1999-10-07 |
2002-08-20 |
Amgen Inc |
Inhibidores de triazina cinasa.
|
|
KR20030024659A
(ko)
|
2000-02-17 |
2003-03-26 |
암겐 인코포레이티드 |
키나제 억제제
|
|
GB0004890D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004888D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0004887D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
CA2406562C
(en)
*
|
2000-05-08 |
2009-09-15 |
Janssen Pharmaceutica N.V. |
Hiv replication inhibiting pyrimidines and triazines
|
|
US7034019B2
(en)
|
2000-05-08 |
2006-04-25 |
Janssen Pharmaceutica N.V. |
Prodrugs of HIV replication inhibiting pyrimidines
|
|
GB0016877D0
(en)
*
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1313729B1
(de)
|
2000-08-17 |
2007-03-21 |
Lumera Corporation |
Design und synthese von nlo-materialien für electro-optische anwendungen, die von thiophen abgeleitet sind
|
|
GB0021726D0
(en)
*
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
|
US6610677B2
(en)
|
2000-09-15 |
2003-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US7473691B2
(en)
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
EP1698627A1
(de)
*
|
2000-09-15 |
2006-09-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazolverbindungen als Protein-Kinasehemmer
|
|
AU2001290912A1
(en)
|
2000-09-15 |
2002-03-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6660731B2
(en)
*
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US20020137755A1
(en)
*
|
2000-12-04 |
2002-09-26 |
Bilodeau Mark T. |
Tyrosine kinase inhibitors
|
|
US7129242B2
(en)
|
2000-12-06 |
2006-10-31 |
Signal Pharmaceuticals, Llc |
Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
|
|
US7122544B2
(en)
|
2000-12-06 |
2006-10-17 |
Signal Pharmaceuticals, Llc |
Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
|
|
MXPA03005696A
(es)
*
|
2000-12-21 |
2003-10-06 |
Glaxo Group Ltd |
Pirimidinaminas como moduladores de angiogenesis.
|
|
BR0116493A
(pt)
|
2000-12-21 |
2003-09-30 |
Vertex Pharma |
Compostos de pirazol úteis como inibidores de proteìna cinase
|
|
AU2006201228B2
(en)
*
|
2000-12-21 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Pyrazole Compounds Useful as Protein Kinase Inhibitors
|
|
ES2257461T3
(es)
|
2000-12-21 |
2006-08-01 |
Bristol-Myers Squibb Company |
Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
|
|
US6756374B2
(en)
|
2001-01-22 |
2004-06-29 |
Hoffmann-La Roche Inc. |
Diaminothiazoles having antiproliferative activity
|
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0107901D0
(en)
*
|
2001-03-29 |
2001-05-23 |
Cyclacel Ltd |
Anti-cancer compounds
|
|
DE10127581A1
(de)
*
|
2001-05-29 |
2003-01-02 |
Schering Ag |
CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
|
IL159120A0
(en)
*
|
2001-05-29 |
2004-05-12 |
Schering Ag |
Cdk inhibiting pyrimidines, production thereof and their use as medicaments
|
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
|
CA2450934A1
(en)
*
|
2001-06-19 |
2002-12-27 |
Marco Dodier |
Pyrimidine inhibitors of phosphodiesterase (pde) 7
|
|
AU2002316421B2
(en)
*
|
2001-06-26 |
2008-05-15 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-ALPHA expression
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
*
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
WO2003026665A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
|
JP4460292B2
(ja)
*
|
2001-10-17 |
2010-05-12 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
|
|
EP1453516A2
(de)
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
|
SE0104140D0
(sv)
*
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
EP1465900B1
(de)
|
2002-01-10 |
2008-05-14 |
Bayer HealthCare AG |
Rho-kinase inhibitoren
|
|
MXPA04007191A
(es)
|
2002-01-23 |
2005-03-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirimidina como inhibidores de rho-quinasa.
|
|
CA2473910C
(en)
|
2002-01-23 |
2011-03-15 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
|
TW200302728A
(en)
|
2002-02-01 |
2003-08-16 |
Novartis Ag |
Substituted amines as IgE inhibitors
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
KR20040084896A
(ko)
*
|
2002-02-06 |
2004-10-06 |
버텍스 파마슈티칼스 인코포레이티드 |
Gsk-3의 억제제로서 유용한 헤테로아릴 화합물
|
|
US7459455B2
(en)
|
2002-02-08 |
2008-12-02 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
|
DK1478358T3
(da)
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
|
NZ535349A
(en)
|
2002-03-08 |
2007-01-26 |
Signal Pharm Inc |
JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
|
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2003076434A1
(en)
|
2002-03-09 |
2003-09-18 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
|
DE10212100A1
(de)
*
|
2002-03-11 |
2003-10-23 |
Schering Ag |
CDK inhibitorische 2-Heteroaryl-Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
|
JP2005526765A
(ja)
*
|
2002-03-11 |
2005-09-08 |
シエーリング アクチエンゲゼルシャフト |
Cdk−阻害性2−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
|
|
US7288547B2
(en)
|
2002-03-11 |
2007-10-30 |
Schering Ag |
CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
|
|
US20040009981A1
(en)
*
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
|
GB0206215D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
US7176310B1
(en)
|
2002-04-09 |
2007-02-13 |
Ucb Sa |
Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
|
|
WO2003095448A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
|
WO2003106451A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Altana Pharma Ag |
Substituted diaminopyrimidines
|
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
ES2373226T3
(es)
|
2002-06-28 |
2012-02-01 |
Astellas Pharma Inc. |
Derivado de diaminopirimidincarboxamida.
|
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
|
IL166241A0
(en)
*
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
KR101297924B1
(ko)
*
|
2002-07-29 |
2013-08-20 |
리겔 파마슈티칼스, 인크. |
2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법
|
|
EP2316459B1
(de)
*
|
2002-07-29 |
2013-11-06 |
Rigel Pharmaceuticals, Inc. |
2,4-Pyrimidindiaminen zur Behandlung oder Vorbeugung von Autoimmunerkrankungen
|
|
RU2376992C2
(ru)
*
|
2002-07-29 |
2009-12-27 |
Райджел Фармасьютикалз, Инк. |
Способы лечения или профилактики аутоиммунных заболеваний с помощью соединений 2,4-пиримидиндиамина
|
|
MXPA05001367A
(es)
|
2002-08-02 |
2005-04-28 |
Vertex Pharma |
Composiciones de pirazol utiles como inhibidores de gsk-3.
|
|
DE10239042A1
(de)
|
2002-08-21 |
2004-03-04 |
Schering Ag |
Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
UA80767C2
(en)
*
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
|
SI1625121T1
(sl)
*
|
2002-12-20 |
2010-04-30 |
Pfizer Prod Inc |
Derivati pirimidina za zdravljenje abnormalne rasti celic
|
|
WO2004072029A2
(en)
*
|
2003-02-06 |
2004-08-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyridazines useful as inhibitors of protein kinases
|
|
US7157455B2
(en)
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
|
ES2325440T3
(es)
*
|
2003-02-20 |
2009-09-04 |
Smithkline Beecham Corporation |
Compuestos de pirimidina.
|
|
CL2004000303A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
|
|
RU2400477C2
(ru)
*
|
2003-03-14 |
2010-09-27 |
Новартис Аг |
2,4-ди(фениламино)пиримидины, применимые при лечении неопластических заболеваний, воспалительных нарушений и нарушений иммунной системы
|
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
|
EP1636585B2
(de)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl-harnstoffe mit kinasehemmender wirkung
|
|
US7504396B2
(en)
|
2003-06-24 |
2009-03-17 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
|
JP4712702B2
(ja)
|
2003-07-24 |
2011-06-29 |
バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト |
高増殖性疾患を処置するために有用な置換されたテトラヒドロベンゾチエノピリミジンアミン化合物
|
|
ES2421139T3
(es)
*
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
RU2356901C2
(ru)
*
|
2003-07-30 |
2009-05-27 |
Райджел Фармасьютикалз, Инк. |
Соединения 2, 4-пиримидиндиамина, обладающие воздействием при аутоиммунных расстройствах
|
|
DK1663242T3
(da)
|
2003-08-07 |
2011-08-01 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
|
|
ATE542801T1
(de)
|
2003-08-15 |
2012-02-15 |
Novartis Ag |
Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
|
|
GB0321710D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
|
DE10349423A1
(de)
|
2003-10-16 |
2005-06-16 |
Schering Ag |
Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
ES2328820T3
(es)
|
2003-10-17 |
2009-11-18 |
Astrazeneca Ab |
Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer.
|
|
CN1902193B
(zh)
*
|
2003-12-04 |
2011-07-13 |
沃泰克斯药物股份有限公司 |
可用作蛋白激酶抑制剂的喹喔啉
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2005080350A1
(en)
*
|
2004-02-23 |
2005-09-01 |
Glaxo Group Limited |
Pyrimidine derivatives as cannabinoid receptor modulators
|
|
WO2005095382A1
(ja)
*
|
2004-03-30 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
抗腫瘍剤
|
|
AU2005231507B2
(en)
|
2004-04-08 |
2012-03-01 |
Targegen, Inc. |
Benzotriazine inhibitors of kinases
|
|
JP2007532669A
(ja)
*
|
2004-04-13 |
2007-11-15 |
イカジェン インコーポレイテッド |
カリウムイオンチャネル調節剤としての多環式ピリミジン
|
|
US7211576B2
(en)
|
2004-04-20 |
2007-05-01 |
Hoffmann-La Roche Inc. |
Diaminothiazoles
|
|
MXPA06013164A
(es)
|
2004-05-14 |
2007-02-13 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
|
|
MXPA06011658A
(es)
|
2004-05-14 |
2006-12-14 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
|
|
EP1758887A1
(de)
|
2004-05-14 |
2007-03-07 |
Pfizer Products Incorporated |
Pyrimidinderivate zur behandlung von anormalem zellwachstum
|
|
JP4812763B2
(ja)
*
|
2004-05-18 |
2011-11-09 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
|
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
|
US7405220B2
(en)
|
2004-06-09 |
2008-07-29 |
Hoffmann-La Roche Inc. |
Pyrazolopyrimidines
|
|
US7521457B2
(en)
*
|
2004-08-20 |
2009-04-21 |
Boehringer Ingelheim International Gmbh |
Pyrimidines as PLK inhibitors
|
|
GB0419160D0
(en)
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
|
ATE542802T1
(de)
*
|
2004-09-30 |
2012-02-15 |
Tibotec Pharm Ltd |
Hiv-inhibierende 5-substituierte pyrimidine
|
|
US8575342B2
(en)
*
|
2004-09-30 |
2013-11-05 |
Tibotech Pharmaceuticals Ltd. |
HIV inhibiting 5-heterocyclyl pyrimidines
|
|
ATE520672T1
(de)
*
|
2004-09-30 |
2011-09-15 |
Tibotec Pharm Ltd |
Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
|
|
GB2420559B
(en)
*
|
2004-11-15 |
2008-08-06 |
Rigel Pharmaceuticals Inc |
Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
|
|
MX2007005857A
(es)
|
2004-11-17 |
2007-10-10 |
Mikana Therapeutics Inc |
Inhibidores de cinasa.
|
|
ATE540035T1
(de)
|
2004-11-24 |
2012-01-15 |
Rigel Pharmaceuticals Inc |
Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
MY169441A
(en)
*
|
2004-12-08 |
2019-04-11 |
Janssen Pharmaceutica Nv |
2,4, (4,6) pyrimidine derivatives
|
|
US20090099160A1
(en)
*
|
2004-12-17 |
2009-04-16 |
David Andrews |
4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors
|
|
US8211929B2
(en)
|
2004-12-30 |
2012-07-03 |
Exelixis, Inc. |
Pyrimidine derivatives as kinase modulators and method of use
|
|
MX2007008434A
(es)
|
2005-01-19 |
2007-07-25 |
Squibb Bristol Myers Co |
Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
|
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
KR101362621B1
(ko)
|
2005-02-16 |
2014-02-13 |
아스트라제네카 아베 |
화합물
|
|
US8227455B2
(en)
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
|
JP2008540436A
(ja)
*
|
2005-05-03 |
2008-11-20 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jakキナーゼインヒビターおよびそれらの使用
|
|
CA2608009A1
(en)
*
|
2005-05-16 |
2006-11-23 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
|
|
WO2006133426A2
(en)
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
EA200800285A1
(ru)
*
|
2005-07-11 |
2008-08-29 |
Санофи-Авентис |
Новые производные 2,4-дианилинопиримидинов, их получение, лекарственные средства, фармацевтические композиции, содержащие указанные производные, и их применение, в частности, в качестве ингибиторов ikk
|
|
FR2888239B1
(fr)
*
|
2005-07-11 |
2008-05-09 |
Sanofi Aventis Sa |
Nouveaux derives de 2,4-dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
|
|
BRPI0614502A2
(pt)
*
|
2005-07-30 |
2011-03-29 |
Astrazeneca Ab |
Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto
|
|
US7737151B2
(en)
*
|
2005-08-18 |
2010-06-15 |
Vertex Pharmaceuticals Incorporated |
Pyrazine kinase inhibitors
|
|
WO2007032445A1
(ja)
*
|
2005-09-16 |
2007-03-22 |
Kyowa Hakko Kogyo Co., Ltd. |
タンパク質キナーゼ阻害剤
|
|
AU2006296386A1
(en)
*
|
2005-09-30 |
2007-04-05 |
Astrazeneca Ab |
Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
|
|
BRPI0616630B8
(pt)
|
2005-09-30 |
2021-05-25 |
Miikana Therapeutics Inc |
compostos de pirazol substituídos
|
|
GB0520958D0
(en)
|
2005-10-14 |
2005-11-23 |
Cyclacel Ltd |
Compound
|
|
BRPI0618011A2
(pt)
|
2005-10-28 |
2011-08-16 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
|
|
AU2012230091B2
(en)
*
|
2005-11-01 |
2015-04-23 |
Impact Biomedicines, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
WO2007053452A1
(en)
|
2005-11-01 |
2007-05-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
JP5249770B2
(ja)
*
|
2005-11-03 |
2013-07-31 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼインヒビターとして有用なアミノピリジン
|
|
US7705009B2
(en)
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
|
US7713987B2
(en)
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
|
EP1966207A2
(de)
|
2005-12-21 |
2008-09-10 |
Pfizer Products Inc. |
Pyrimidinderivate zur behandlung von anormalem zellwachstum
|
|
DE102005062742A1
(de)
|
2005-12-22 |
2007-06-28 |
Bayer Schering Pharma Ag |
Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
|
|
US9598669B2
(en)
|
2005-12-29 |
2017-03-21 |
Anthrogenesis Corporation |
Composition for collecting placental stem cells and methods of using the composition
|
|
WO2007098507A2
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
AU2007233737B2
(en)
*
|
2006-03-30 |
2012-11-29 |
Janssen Sciences Ireland Uc |
HIV inhibiting 5-amido substituted pyrimidines
|
|
PE20080068A1
(es)
*
|
2006-05-15 |
2008-03-17 |
Boehringer Ingelheim Int |
Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
|
|
AU2007269540B2
(en)
|
2006-07-05 |
2013-06-27 |
Exelixis, Inc. |
Methods of using IGF1R and Abl kinase modulators
|
|
DK2089369T3
(da)
|
2006-10-19 |
2011-05-09 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
|
|
MX2009004426A
(es)
|
2006-10-23 |
2009-08-12 |
Cephalon Inc |
Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
|
|
CA2668429A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
|
JP5208123B2
(ja)
*
|
2006-12-08 |
2013-06-12 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤としての化合物および組成物
|
|
EA019941B1
(ru)
|
2006-12-08 |
2014-07-30 |
АйАрЭм ЭлЭлСи |
Соединения и композиции в качестве ингибиторов протеинкиназы
|
|
NZ577768A
(en)
*
|
2006-12-19 |
2012-01-12 |
Vertex Pharma |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
US9006243B2
(en)
*
|
2006-12-29 |
2015-04-14 |
Janssen R&D Ireland |
HIV inhibiting 6-substituted pyrimidines
|
|
US8318736B2
(en)
|
2006-12-29 |
2012-11-27 |
Janssen R&D Ireland |
HIV inhibiting 5,6-substituted pyrimidines
|
|
JPWO2008111441A1
(ja)
|
2007-03-05 |
2010-06-24 |
協和発酵キリン株式会社 |
医薬組成物
|
|
NZ579483A
(en)
|
2007-03-09 |
2012-07-27 |
Vertex Pharma |
Aminopyridines useful as inhibitors of protein kinases
|
|
CN101663295B
(zh)
*
|
2007-03-09 |
2014-11-05 |
沃泰克斯药物股份有限公司 |
可用作蛋白激酶抑制剂的氨基嘧啶类化合物
|
|
JP5393489B2
(ja)
*
|
2007-03-09 |
2014-01-22 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
蛋白キナーゼの阻害剤として有用なアミノピリミジン
|
|
MX2009011059A
(es)
|
2007-04-13 |
2009-11-26 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de cinasas.
|
|
AU2008247594A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
CA2688584A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
WO2008137619A2
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
AU2008257044A1
(en)
*
|
2007-05-24 |
2008-12-04 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
WO2009018415A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
|
RU2490015C2
(ru)
|
2008-02-22 |
2013-08-20 |
Райджел Фармасьютикалз, Инк. |
Применение 2,4-пиримидиндиаминов для лечения атеросклероза
|
|
KR20100132550A
(ko)
|
2008-04-16 |
2010-12-17 |
포톨라 파마슈티컬스, 인코포레이티드 |
syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
BRPI0910668A2
(pt)
|
2008-04-22 |
2019-09-24 |
Portola Pharmaceutiacals Inc |
inibidores de proteína quinases
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AU2009262068C1
(en)
*
|
2008-06-27 |
2015-07-02 |
Celgene Car Llc |
Heteroaryl compounds and uses thereof
|
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AU2009288200A1
(en)
*
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
|
TW201016676A
(en)
*
|
2008-10-03 |
2010-05-01 |
Astrazeneca Ab |
Heterocyclic derivatives and methods of use thereof
|
|
EP2179992A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
EP2179991A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
EP2179993A1
(de)
|
2008-10-21 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
SG173647A1
(en)
|
2009-02-13 |
2011-10-28 |
Shionogi & Co |
Novel triazine derivative and pharmaceutical composition containing same
|
|
DE102009001438A1
(de)
|
2009-03-10 |
2010-09-16 |
Bayer Schering Pharma Aktiengesellschaft |
Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
US20110071158A1
(en)
*
|
2009-03-18 |
2011-03-24 |
Boehringer Ingelheim International Gmbh |
New compounds
|
|
DE102009015070A1
(de)
|
2009-03-30 |
2010-10-14 |
Bayer Schering Pharma Aktiengesellschaft |
Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
KR101705158B1
(ko)
|
2009-05-05 |
2017-02-09 |
다나-파버 캔서 인스티튜트 인크. |
Egfr 억제제 및 질환 치료방법
|
|
MX337849B
(es)
*
|
2009-07-28 |
2016-03-09 |
Rigel Pharmaceuticals Inc |
Composiciones y metodos para inhibicion de la via jak.
|
|
EP2464642A4
(de)
*
|
2009-08-12 |
2013-01-09 |
Poniard Pharmaceuticals Inc |
Verfahren zur förderung von apoptose und zur metastasenhemmung
|
|
AR077999A1
(es)
|
2009-09-02 |
2011-10-05 |
Vifor Int Ag |
Antagonistas de pirimidin y triazin-hepcidina
|
|
WO2011065800A2
(ko)
*
|
2009-11-30 |
2011-06-03 |
주식회사 오스코텍 |
피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
|
|
DE102010014426A1
(de)
|
2010-04-01 |
2011-10-06 |
Bayer Schering Pharma Aktiengesellschaft |
Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
|
|
DE102010014427A1
(de)
|
2010-04-01 |
2011-10-06 |
Bayer Schering Pharma Aktiengesellschaft |
Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
|
|
WO2011159726A2
(en)
|
2010-06-14 |
2011-12-22 |
The Scripps Research Institute |
Reprogramming of cells to a new fate
|
|
CA2803004A1
(en)
|
2010-06-29 |
2012-01-12 |
Poniard Pharmaceuticals, Inc. |
Oral formulations of kinase inhibitors
|
|
CN103168037A
(zh)
|
2010-06-30 |
2013-06-19 |
博尼亚德医药品股份有限公司 |
激酶抑制剂的合成和用途
|
|
WO2012020742A1
(ja)
|
2010-08-10 |
2012-02-16 |
塩野義製薬株式会社 |
新規複素環誘導体およびそれらを含有する医薬組成物
|
|
US9718790B2
(en)
|
2010-08-10 |
2017-08-01 |
Shionogi & Co., Ltd. |
Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
|
|
PH12013500246A1
(en)
|
2010-08-10 |
2019-10-11 |
Celgene Avilomics Res Inc |
Besylate salt of a btk inhibitor
|
|
WO2012061415A1
(en)
|
2010-11-01 |
2012-05-10 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
|
BR112013010564B1
(pt)
|
2010-11-01 |
2021-09-21 |
Celgene Car Llc |
Compostos heterocíclicos e composições compreendendo os mesmos
|
|
JP5956999B2
(ja)
|
2010-11-01 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
ヘテロアリール化合物およびその使用
|
|
EP2975027A1
(de)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamide als jak-kinasemodulatoren
|
|
AU2011323484B2
(en)
|
2010-11-01 |
2016-10-06 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as Syk modulators
|
|
AU2010363329A1
(en)
|
2010-11-07 |
2013-05-09 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
EP2637502B1
(de)
|
2010-11-10 |
2018-01-10 |
Celgene CAR LLC |
Mutanten-selektive egfr-hemmer und verwendungen davon
|
|
DK2675794T3
(da)
|
2011-02-17 |
2019-05-06 |
Cancer Therapeutics Crc Pty Ltd |
Selektive fak-inhibitorer
|
|
WO2012110773A1
(en)
|
2011-02-17 |
2012-08-23 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
|
JP2014532658A
(ja)
|
2011-10-28 |
2014-12-08 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
ブルトン型チロシンキナーゼ疾患または障害を治療する方法
|
|
EP2782579B1
(de)
|
2011-11-23 |
2019-01-02 |
Portola Pharmaceuticals, Inc. |
Pyrazinkinaseinhibitoren
|
|
JP6124351B2
(ja)
|
2012-02-09 |
2017-05-10 |
塩野義製薬株式会社 |
複素環および炭素環誘導体
|
|
JP6317320B2
(ja)
|
2012-03-15 |
2018-04-25 |
セルジーン シーエーアール エルエルシー |
上皮成長因子受容体キナーゼ阻害剤の塩
|
|
ES2880109T3
(es)
|
2012-03-15 |
2021-11-23 |
Celgene Car Llc |
Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
|
|
AU2013234451A1
(en)
|
2012-03-21 |
2014-09-25 |
Bayer Intellectual Property Gmbh |
Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
|
|
CA2871589C
(en)
*
|
2012-05-18 |
2020-12-22 |
Seiji Hori |
Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
|
|
JP2015517574A
(ja)
*
|
2012-05-22 |
2015-06-22 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
がん治療のためのピリミジン化合物
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
CA2890935A1
(en)
*
|
2012-11-08 |
2014-05-15 |
Bristol-Myers Squibb Company |
Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
|
|
WO2014085225A1
(en)
*
|
2012-11-27 |
2014-06-05 |
The University Of North Carolina At Chapel Hill |
Pyrimidine compounds for the treatment of cancer
|
|
US9126950B2
(en)
|
2012-12-21 |
2015-09-08 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CN103059030B
(zh)
*
|
2012-12-28 |
2015-04-29 |
北京师范大学 |
一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
|
|
CN105188371A
(zh)
|
2013-02-08 |
2015-12-23 |
西建阿维拉米斯研究公司 |
Erk抑制剂及其用途
|
|
US9346802B2
(en)
|
2013-03-15 |
2016-05-24 |
Epizyme, Inc. |
CARM1 inhibitors and uses thereof
|
|
WO2014144169A1
(en)
|
2013-03-15 |
2014-09-18 |
Epizyme, Inc. |
Carm1 inhibitors and uses thereof
|
|
EP2970266B1
(de)
|
2013-03-15 |
2018-01-31 |
Epizyme, Inc. |
1-phenoxy-3-(alkylamino)-propanol-2-derivate als carm1-inhibitoren und verwendung davon
|
|
WO2014173815A1
(en)
|
2013-04-23 |
2014-10-30 |
Bayer Pharma Aktiengesellschaft |
Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
|
|
CN103333119A
(zh)
*
|
2013-05-28 |
2013-10-02 |
中国药科大学 |
1,2-二氢-6-甲基-4-取代氨基-5-嘧啶羧酸类化合物及其制备方法和用途
|
|
TWI637949B
(zh)
|
2013-06-14 |
2018-10-11 |
塩野義製藥股份有限公司 |
胺基三衍生物及含有其等之醫藥組合物
|
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
|
RS62017B1
(sr)
*
|
2014-09-17 |
2021-07-30 |
Celgene Car Llc |
Mk2 inhibitori i njihova upotreba
|
|
AU2016274576A1
(en)
|
2015-06-11 |
2017-12-21 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
p62-ZZ chemical inhibitor
|
|
CN106588885B
(zh)
*
|
2016-11-10 |
2019-03-19 |
浙江大学 |
2-取代芳环-嘧啶类衍生物及制备和应用
|
|
CN107903256B
(zh)
*
|
2017-11-29 |
2019-11-15 |
南方医科大学 |
一种含取代噻唑的2,4-二氨基嘧啶及其应用
|
|
KR102782739B1
(ko)
*
|
2018-03-13 |
2025-03-20 |
보로노이 주식회사 |
2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
|
|
KR102901976B1
(ko)
*
|
2018-03-13 |
2025-12-24 |
보로노이 주식회사 |
2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
|
|
AU2020300619A1
(en)
|
2019-07-03 |
2022-01-27 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
|
CN112390760B
(zh)
*
|
2020-10-15 |
2022-07-29 |
北京师范大学 |
靶向fak的化合物及其制备方法和应用
|
|
CA3240810A1
(en)
*
|
2021-12-13 |
2023-06-22 |
Signet Therapeutics Inc. |
Pyrimidine or pyridine derivative and pharmaceutical use thereof
|
|
KR102939283B1
(ko)
*
|
2022-05-03 |
2026-03-13 |
한국화학연구원 |
5-클로로-2,4-다이아미노피리미딘을 포함하는 키나아제 억제 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN115677595B
(zh)
*
|
2022-10-26 |
2024-06-14 |
江苏睿实生物科技有限公司 |
一种2,4,5-三氯嘧啶的制备方法
|